背景:关于COVID-19大流行主题的科学研究正走向科学文献的爆炸式增长。尽管有这些全球性的努力,患者的有效治疗是一个正在进行的挑战。基于对过去六十年中已发表的有关化合物及其植物来源的证据的荟萃研究,已开发出一种新型的多适应症草药化合物(Saliravira®)。基于抗病毒,抗炎,和其成分的免疫增强特性,我们假设Saliravira®具有作为抗病毒剂的潜力,加速治疗,并减少COVID-19的不良作用。
方法:在本随机分组中,控制,开放标签临床试验,COVID-19门诊患者根据症状通过RT-PCR检测或医师诊断纳入。参与者被随机分为干预组和对照组,接受Saliravira®包加COVID-19常规治疗或单纯COVID-19常规治疗,分别。Saliravira®包装包括片剂,鼻窦喷雾剂,口咽喷雾剂,和吸入器滴剂。治疗10天,随访至入院后23天。
结果:在第8天,干预组患者的病毒载量“平均减少率”比对照组低50%,p值<0.05.干预组14例COVID-19症状中10例的改善明显加快。干预组患者的平均治疗时间比对照组少4.9天。此外,干预组没有患者住院,而对照组有28%的患者需要住院.
BACKGROUND: The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-
study of published shreds of evidence about compounds and their botanic sources in the last six decades, a novel multiple-indication herbal compound (Saliravira®) has been developed. Based on the antiviral, anti-inflammatory, and immune-enhancing properties of its ingredients, we hypothesized that Saliravira® has the potential to act as an antiviral agent, accelerate treatment, and reduce undesirable effects of COVID-19.
METHODS: In this randomized, controlled, open-label clinical
trial, COVID-19 outpatients were included by RT-PCR test or diagnosis of physicians according to the symptoms. Participants were randomly divided into intervention and control groups to receive Saliravira® package plus routine treatments of COVID-19 or routine treatments of COVID-19 alone, respectively. Saliravira® package includes tablets, nasal-sinuses spray, oral-pharynx spray, and inhaler drops. The treatment was for 10 days and followed up till 23 days after admission.
RESULTS: On the 8th day, the \"mean reduction rates\" of viral load of the patients in the intervention group was 50% lower compared to the control group with a p-value < 0.05. The improvement of 10 out of 14 COVID-19 symptoms in the intervention group was significantly accelerated. The mean treatment duration of patients in the intervention group was 4.9 days less than the control group. In addition, no patients in the intervention group were hospitalized compared to 28% of the control group needed to be hospitalized.